Today
+5.64%
5 Days
+4.24%
1 Month
+15.87%
6 Months
-19.09%
Year to Date
-7.75%
1 Year
+5.34%
• HCA Healthcare reported strong quarterly operating results driven by robust patient admissions. • Institutional accumulation and strategic outpatient expansion reinforced positive investor sentiment and price momentum. • The company achieved annual revenue of $75.60B and net profit of $6.78B.
• Abbott Laboratories shares declined due to litigation risks and medical device division concerns. • Legal proceedings regarding infant formula claims continue to negatively impact institutional sentiment. • Increased competition and pricing pressures contributed to analyst downward adjustments in growth estimates.
• Intuitive Surgical shares declined due to concerns over decelerating elective procedure volume growth. • Increased competition and hospital capital budget constraints challenge long-term market share assumptions. • Analysts adjusted forecasts amid uncertainties regarding regulatory approvals and high valuation multiples.
• Stryker shares declined due to concerns over decelerating hospital capital equipment spending. • Increased competition in the orthopedic market threatens Stryker’s premium pricing power and margins. • Macroeconomic factors, including labor inflation and foreign exchange, are pressuring company earnings.
• HCA Healthcare reported Q1 2026 results meeting analyst expectations. • Lower patient volumes and milder respiratory season impacted HCA Healthcare's Q1. • HCA Healthcare's stock declined despite meeting earnings expectations.
• Boston Scientific Q1 results beat estimates, but guidance was lowered. • Full-year 2026 profit and revenue growth forecasts were reduced. • Headwinds in key segments and a lawsuit impacted the stock.


| Shareholders | Proportion |
|---|---|
| Frist Capital, L.L.C. | 16.48% |
| Hercules Holding II | 14.55% |
| Sanders Capital, LLC | 4.72% |
| Vanguard Capital Management, LLC | 4.59% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 35.34% |
| Investment Advisor/Hedge Fund | 19.03% |
| Private Equity | 16.48% |
| Corporation | 14.55% |
Related Instruments
Popular Instruments